Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
1 clinical trials · Condition
◉ Watch Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
| Record | Firm | Date |
|---|---|---|
| Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (NCT03907488) | National Cancer Institute (NCI) | 2019-08-29 |
Track Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.